PMID- 21116029
OWN - NLM
STAT- MEDLINE
DCOM- 20110329
LR  - 20221207
IS  - 1872-9061 (Electronic)
IS  - 0300-2977 (Linking)
VI  - 68
IP  - 11
DP  - 2010 Nov
TI  - Pronounced weight gain in insulin-treated patients with type 2 diabetes mellitus 
      is associated with an unfavourable cardiometabolic risk profile.
PG  - 359-66
AB  - Pronounced weight gain after start of insulin therapy in patients with type 2 
      diabetes mellitus (T2DM) may offset beneficial effects conferred by the 
      improvement of glycaemic control. This hypothesis was tested by comparing the 
      cardiometabolic risk profile of a group of type 2 diabetes patients with a marked 
      increase in body weight ('gainers) after the start of insulin treatment and a 
      similar group without any or only minimal weight gain ('non-gainers'). In a 
      cross-sectional study, we compared two predefined groups of patients with T2DM 
      who had been on insulin therapy for a mean of 4.0 years: 'gainers' vs 
      'non-gainers'. Cardiometabolic risk was assessed by measuring fat content and 
      distribution (physical examination, bioelectrical impedance analysis, dual energy 
      X-ray absorption, and magnetic resonance imaging), liver fat content (magnetic 
      resonance spectroscopy), physical activity levels (Sensewear(R) armband) and plasma 
      markers. Each subgroup consisted of 14 patients. Gainers had significantly more 
      total body and trunk fat (especially subcutaneous fat) compared with no-gainers. 
      Gainers had similar liver fat content, and slightly higher levels of fat 
      hormones. Furthermore, gainers performed significantly less physical activity. 
      Lastly, gainers had higher total cholesterol, low-density lipoprotein 
      cholesterol, and alanine aminotransferase levels with similar 
      cholesterol-lowering treatment. Patients with T2DM who show pronounced weight 
      gain during insulin therapy have a less favourable cardiometabolic risk profile 
      compared with patients who show no or minimal weight gain.
FAU - Jansen, H J
AU  - Jansen HJ
AD  - Department of Internal Medicine, Radboud University Nijmegen Medical Center, 
      Nijmegen, the Netherlands. H.Jansen@aig.umcn.nl
FAU - Vervoort, G
AU  - Vervoort G
FAU - van der Graaf, M
AU  - van der Graaf M
FAU - Tack, C J
AU  - Tack CJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Netherlands
TA  - Neth J Med
JT  - The Netherlands journal of medicine
JID - 0356133
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Aged
MH  - Body Fat Distribution
MH  - Body Weight/drug effects
MH  - Cardiovascular Diseases/*epidemiology/pathology
MH  - Cross-Sectional Studies
MH  - *Diabetes Complications
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/pathology
MH  - Female
MH  - Glycated Hemoglobin
MH  - Humans
MH  - Hypoglycemic Agents/*adverse effects/therapeutic use
MH  - Insulin/*adverse effects/therapeutic use
MH  - Male
MH  - Metabolic Diseases/epidemiology/pathology
MH  - Metformin/adverse effects
MH  - Middle Aged
MH  - Motor Activity
MH  - Netherlands/epidemiology
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Weight Gain/*drug effects
EDAT- 2010/12/01 06:00
MHDA- 2011/03/30 06:00
CRDT- 2010/12/01 06:00
PHST- 2010/12/01 06:00 [entrez]
PHST- 2010/12/01 06:00 [pubmed]
PHST- 2011/03/30 06:00 [medline]
PST - ppublish
SO  - Neth J Med. 2010 Nov;68(11):359-66.